Common name
4-ethylmorpholine
IUPAC name
4-ethylmorpholine
SMILES
O1CCN(CC1)CC
Common name
4-ethylmorpholine
IUPAC name
4-ethylmorpholine
SMILES
O1CCN(CC1)CC
INCHI
InChI=1S/C6H13NO/c1-2-7-3-5-8-6-4-7/h2-6H2,1H3
FORMULA
C6H13NO
Common name
4-ethylmorpholine
IUPAC name
4-ethylmorpholine
Molecular weight
115.174
clogP
1.159
clogS
-0.802
Frequency
0.0031
HBond Acceptor
2
HBond Donor
0
Total PolarSurface Area
12.47
Number of Rings
1
Rotatable Bond
1
| Drug ID | Common name | Structure CAS | Compound class | Therapeutic area |
|---|---|---|---|---|
| FDBD00203 | Gefitinib |
|
Antineoplastic Agents; Protein Kinase Inhibitors; Antineoplastic and Immunomodulating Agents; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inducers; Cytochrome P-450 CYP2C19 Inducers; CYP2D6 Inducers; CYP2D6 Inducers (strong); CYP3A4 Inhibitors; | For the continued treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of either platinum-based or docetaxel chemotherapies. |
| FDBD00428 | Doxapram |
|
Central Nervous System Stimulants; Respiratory System Agents; Respiratory System; Respiratory Stimulants; | For use as a temporary measure in hospitalized patients with acute respiratory insufficiency superimposed on chronic obstructive pulmonary disease. |
| FDBD00545 | Moricizine |
|
Anti-Arrhythmia Agents; Voltage-Gated Sodium Channel Blockers; Cardiovascular System; Antiarrhythmics, Class I and Iii; Cardiac Therapy; Antiarrythmics, Class I and Iii; | Used to treat irregular heartbeats (arrhythmias) and maintain a normal heart rate. |
| FDBD00667 | Minaprine |
|
Antidepressive Agents; Nervous System; Antidepressants; Psychoanaleptics; CYP2D6 Inducers; CYP2D6 Inducers (strong); | For the treatment of depression. |
| FDBD01017 | Moclobemide |
|
Antidepressive Agents; Monoamine Oxidase Inhibitors; Nervous System; Antidepressants; Psychoanaleptics; Monoamine Oxidase a Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP1A2 Inducers; Cytochrome P-450 CYP2C9 Inducers; Cytochrome P-450 CYP2C19 Inducers; CYP2D6 Inducers; CYP2D6 Inducers (strong); | For the treatment of depression. |
| FDBD01652 | Cobicistat |
|
Anti-HIV Agents; Antiinfectives for Systemic Use; Direct Acting Antivirals; Antivirals for Systemic Use; Cytochrome P-450 CYP3A Inhibitors; CYP2D6 Inducers; CYP2D6 Inducers (strong); | Cobicistat is a CYP3A inhibitor indicated to increase systemic exposure of atazanavir or darunavir (once daily dosing regimen) in combination with other antiretroviral agents in the treatment of HIV-1 infection. It is not interchangeable with ritonavir to increase systemic exposure of darunavir 600 mg twice daily, fosamprenavir, saquinavir, or tipranavir due to lack of exposure data. The use of cobicistat is not recommended with darunavir 600 mg twice daily, fosamprenavir, saquinavir or tipranavir. Complex or unknown mechanisms of drug interactions preclude extrapolation of ritonavir drug interactions to certain cobicistat interactions. Cobicistat and ritonavir when administered with either atazanavir or darunavir may result in different drug interactions when used with concomitant medications. |
| FDBD01672 | Pinaverium |
|
Alimentary Tract and Metabolism; Drugs for Functional Gastrointestinal Disorders; | |
| FDBD01739 | Pholcodine |
|
Cough and Cold Preparations; Respiratory System; Opium Alkaloids and Derivatives; | For use as a cough suppressant. |
| FDBD01818 | Pramocaine |
|
Dermatologicals; Cardiovascular System; Local Anesthetics; Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use; Vasoprotectives; Anesthetics for Topical Use; Antipruritics, Incl. Antihistamines, Anesthetics, Etc.; |
9 ,
1
| FRAGNAME | PDBID | SIMILIRITY | XSCORE | SMILE | HAC |
|---|---|---|---|---|---|
| 4f6u_ligand_2_14.mol2 | 4f6u | 1 | -6.29 | C(C)[NH+]1CCOCC1 | 8 |
| 3hv6_ligand_2_0.mol2 | 3hv6 | 1 | -5.95 | C([NH+]1CCOCC1)C | 8 |
| 1kv2_ligand_2_20.mol2 | 1kv2 | 1 | -5.93 | CC[NH+]1CCOCC1 | 8 |
| 4f70_ligand_2_9.mol2 | 4f70 | 1 | -5.90 | [NH+]1(CCOCC1)CC | 8 |
| 1a7t_ligand_2_0.mol2 | 1a7t | 1 | -5.78 | CC[NH+]1CCOCC1 | 8 |
| 3fzs_ligand_2_20.mol2 | 3fzs | 1 | -5.68 | C([NH+]1CCOCC1)C | 8 |
| 1fq4_ligand_2_117.mol2 | 1fq4 | 1 | -5.67 | O1CC[NH+](CC1)CC | 8 |
| 2vvt_ligand_2_35.mol2 | 2vvt | 1 | -5.57 | CC[NH+]1CCOCC1 | 8 |
| 4q4r_ligand_2_5.mol2 | 4q4r | 1 | -5.48 | [NH+]1(CCOCC1)CC | 8 |
115 ,
12
